GeneLancet Biosciences
1 known investors
GeneLancet develops proprietary LgRNA technology for precise gene editing, with applications in CRISPR polymerase-directed therapies targeting neurodegenerative diseases and cancers with unmet medical needs.
BiotechDeep TechHealthtech